Clinical Trial Update: AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction [Phase 3]

View source ↗

Summary

Phase 3 trial update for Aurion Biotech's AURN001 in corneal edema due to corneal endothelial dysfunction, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Edema
• Corneal Endothelial Dysfunction
• Fuchs Endothelial Corneal Dystrophy
• Pseudophakic Bullous Keratopathy

Drugs mentioned

• AURN001

Snippet

Sponsor: Aurion Biotech | Conditions: Corneal Edema, Corneal Endothelial Dysfunction | Phase 3 | Status: RECRUITING